HOPKINTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP - News) today announced the appointment of Dr. Peter Lassota as the Divisional Vice President of Oncology. Dr. Lassota joins Caliper from the Novartis Institutes for Biomedical Research, where he led Novartis’ U.S. Oncology Pharmacology Unit. At Caliper, Dr. Lassota will lead the research and development activities involved in oncology applications and spearhead the utilization of biophotonic imaging in the development of new technologies for use in biomarker research.
“We are honored to have such a renowned expert in oncology research with the breadth of Dr. Lassota’s experience joining Caliper,” said Kevin Hrusovsky, president and CEO of Caliper. “His understanding of pharma-specific needs and issues is welcome as we expand our offerings for the oncology therapeutic area and continue to provide biotechnology and pharmaceutical companies with solutions that span the continuum of drug discovery and development.”
Dr. Lassota joins Caliper following the company’s acquisition of Xenogen Corporation, an imaging technologies company, earlier this month. In his new role with the company, Dr. Lassota will utilize his extensive experience in oncology-specific imaging research to build upon the company’s line of biophotonic imaging solutions. Caliper believes that the continued development of these imaging tools will accelerate identification, analysis and the use of biomarkers that biotechnology and pharmaceutical companies require to successfully speed new drugs to market.
“I am proud and excited to join Caliper and look forward to being part of the oncology research and development team,” said Dr. Lassota. “Caliper’s growth into the imaging area gives us the opportunity to accelerate the development of solutions that successfully bridge the gap between in vitro and in vivo research.”
In addition to holding various positions at the Novartis Institutes for Biomedical Research, Dr. Lassota spearheaded research in the Department of Oncology and Immunology at Wyeth-Ayerst Research and the American Cyanamid Company. He earned his M.S. in Chemistry from the University of Warsaw, and his Ph.D. in Biochemistry and Biophysics from the Polish Academy of Sciences. Additionally, Dr. Lassota served as a postdoctoral fellow under Dr. Jerard Hurwitz at the Sloan-Kettering Institute for Cancer Research in New York City. He is the author of more than thirty academic papers, has several patented inventions, and is a frequent guest lecturer at conferences and meetings around the world.
About Caliper Life Sciences
Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its recent acquisitions of NovaScreen Biosciences and Xenogen Corp., Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper’s products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at www.caliperLS.com.
NOTE: Caliper is a registered trademark of Caliper Life Sciences, Inc.
Source: Caliper Life Sciences, Inc.
